Please login to the form below

Not currently logged in
Email:
Password:

Janssen/Jubilant alliance

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience.

The alliance, which will see Jubliant develop preclinical drug clients for Janssen to develop and commercialise, is set to last at least three years.

Jubilant is to receive research funding and is eligible for future milestones and royalties depending on the success of drug candidates.

Financial terms were not disclosed.

"The collaboration will utilise Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres," said Sri Mosur, CEO and president, global drug discovery and development, Jubilant.

"We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."

28th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

How to make an impact at a virtual congress
As hard as congress organisers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real...
Live webinar
China: How pharma can maximize success in this rapidly changing emerging market...
brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...

Infographics